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system settings, reimbursement, HTA bodies and evaluation, evidence require-
ments, procurement process, value perception, and key trends and opportunities. 
This data was gathered through a partnership between Pharmerit and Ethicon Inc. A 
targeted literature review was conducted to collect information regarding these top-
ics. If gaps in the knowledge were identified after this review, interviews with local 
affiliates were conducted. Results: Through our methodology and analysis, the 
following results were identified. Brazil is growing and enjoys the largest economy 
and most attractive medical device market in Latin America growing 13.6% (CAGR) 
over the next decade. Health expenditure is valued at US$502 per capita. Brazil has 
200 Million people in the public sector, and 51 Million of those also have private 
insurance. New laws promote the development and purchasing of national products. 
Both the public and private sectors are regulated by the Ministry of Health (MoH) and 
ANVISA for premarket regulatory approval. Pricing is negotiated through tenders 
and purchasing negotiation, and differ by region. At this time Medical Devices do not 
have price regulation, but in 2015 a working group was created by the MoH in order 
to evaluate and regulate medical devices’ prices. HTA has grown rapidly leading to 
constrictions in adoption of new technologies and market access. New guidelines 
were prepared specifically for medical devices (HTA by CONITEC) in order to promote 
a better evaluation for medical devices.
RESEARCH PODIUM PRESENTATIONS – SESSION II
BUDGET IMPACT AND COST STUDIES
BI1
COST REDUCTION FOR A HEAlTH SySTEM THROUGH DECREASING NUMBER 
OF ElIGIBlE PATIENTS FOR BIOlOGICAl THERAPy IN PATIENTS WITH 
RHEUMATOID ARTHRITIS USING THE TREAT TO TARGET RECOMMENDATIONS
Santos-Moreno P, Saavedra-Martínez G, Bello-Gualtero J, Gómez-Mora D
Biomab, Centro de Artritis Reumatoide, Bogota, Colombia
Objectives: Biological therapy is a major therapeutic tool to prevent clinical and 
radiological progression of rheumatoid arthritis (RA), however due to the high 
cost of it is not possible to use extensively in Colombia. The aim of this study 
was to describe the reduction in Disease Activity Score 28 (DAS28) in patients 
with moderate-severe disease activity (MDA/SDA), by using strictly a Treat to 
Target (T2T) strategy for 24 and subsequently cost-savings obtained. MethOds: 
A descriptive cross-sectional study was performed. Records of patients with mod-
erate or severe disease activity (MDA/SDA) were reviewed; patients were consid-
ered potential candidates for biologic therapies and were followed-up under T2T 
standards. The aim of the study was to look at what percentage of patients who 
were in MDA/SDA disease activity reached a remission/low disease activity (Rem/
LDA) status. Descriptive epidemiology, the medians were analyzed using t-Student 
and disease activity was analyzed using Pearson´s statistics. Were analyzed cost-
savings obtained through decreasing the number of eligible patients for biological 
therapy. Results: 622 patients were included in this study, 453 (72.8%) women 
and 169 (27.2%) men. These patients came in moderate or severe disease activity 
with DAS28 3.5 in average; at 24 months with T2T strategy using only conventional 
DMARS 467 patients (75.1%) got remission/low disease activity status with a DAS28 
2.6 in average. The costs of biological therapy finishing 2014 on average was 16.595 
US dollars/year/patient, and for 467 patients amount in projected costs-savings of 
preventing use of biologics was approximately 5’824.849 US dollars/year, ranging 
between the cheaper biological and the most expensive (2’975.228 and 7’749.865 
US dollars/year) respectively. cOnclusiOns: The results of study showed that 
is possible to decrease disease activity and obtain a significant cost-reduction in 
RA by using only conventional DMARDs in a model with defined therapeutic goals 
like T2T and optimizing a multidisciplinary approach.
BI2
TREATMENT PATTERNS AND BUDGETARy IMPACT OF CHEMOTHERAPy DRUGS 
IN A BRAzIlIAN PRIvATE HEAlTH PlAN (PHP)
Nishikawa AM1, Castro AP1, Alves AF1, Medina P1, Clark LG2
1Evidências - Kantar Health, Campinas, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil
Objectives: According to GLOBOSCAN 2012 and WHO, 14.1 million new cancer 
cases and 8.2 million deaths occurred worldwide in 2012. In Brazil, the incidence of 
the disease is also increasing as population ages, with 576,000 new cases of cancer 
expected in 2015. Despite the significant impact of disease and need for monitor-
ing and prevention, epidemiological and economic data that would help decision 
markers to evaluate unmet needs are still scarce. This study aims to evaluate the epi-
demiological aspects; economic impact and treatment patterns in a private health 
insurance plan with approximately 150,000 lives. MethOds: We retrieved data from 
Evidências-Kantar Health private market administrative claims database from June 
2012 to June 2013. After patient de-identification, data on diagnosis, type of drug, and 
line-of-treatment were collected. All ICDs and treatment patterns were reviewed by 
an oncologist. Health economist specialists priced the treatments (ex-factory price) 
in order to assess the budgetary impact. Only oncologic drug costs were considered 
– antiemetics, corticosteroids and equipment were not included). Exchange rate was 
1USD= 3.25BRL. Results: A total of 150 new cases of cancer were retrieved from the 
database. Median age was 59.5years (3 – 89) and body surface 1.775 m2 (0.72 – 2.3). 
The five most prevalent cancers were breast (19%), colon (15%), prostate (11%), non-
Hodgkin’s lymphoma (7%) and lung neoplasm (5%). The budget impact for cancer 
treatments was USD 1,464,958, (most impacting diseases: USD436,908 for breast, 
USD428,90 for colorectal and USD177,131 for non-Hodgkin lymphoma). Considering 
the average cost per patient treated, kidney (USD27,970), colon (USD19,495) and 
brain cancer (USD17,809) were the most expensive ones. Treatment pattern will be 
described in details in tables. cOnclusiOns: The increasing incidence of cancer 
and its costly treatments are significantly affecting the economic sustainability of 
the healthcare sector. This study maps the most prevalent and costly cancer treat-
ments under a private insurance perspective in Brazil.
was done. Results: TLR Avoided probability with DCB was 0,856 vs. 0,600 for PTA. 
DCB total cost was R$4.468 vs. R$3.737 for PTA. The ICER was R$2.856. In univariate 
sensitivity the ICER the total DCB cost was tested from -10% to +10%, obtaining ICER 
values that were from R$2.075 to R$3.637. In the Probabilistic Sensitivity analysis, 
it was a 24% probability for DCB to be dominant or cost-saving, and 98,3% of been 
under 3 GDP per Capita for Brazil. cOnclusiOns: DCB showed a 98,3% probability 
of been cost-effectiveness when compared to PTA and a 24% probability of been 
cost-saving.
PRICING AND HEAlTH SySTEM STUDIES
PR2
COMPETITION AND STRATEGIC REGUlATION IN THE ARGENTINE 
PHARMACEUTICAl MARkET: A COMPARATIvE STUDy OF SIx THERAPEUTIC 
ClASSES
Maceira D, Palacios A
Center for the Study of State and Society (CEDES), Buenos Aires, Argentina
Objectives: To analyze how main determinants of competition in six therapeutic 
target groups -analgesics, tranquilizers, peptic ulcer treatment, cholesterol treat-
ment, benign prostatic hypertrophy and ACE inhibitors- were affected by regula-
tions and drug policies implemented at national level during the last decade in 
the pharmaceutical market in Argentina. MethOds: The database corresponds 
to the annual information on retail sales in the Argentine pharmaceutical sector 
generated by IMS for the period 2005-2012. The estimation strategy takes the form 
of econometric models of ordinary least squares with year fixed effects and robust 
standard errors. The dependent variables explain the market shares of each product/
brand per therapeutic class, explained by prices, participant active principles, and 
a set of variables capturing product differentiation mechanisms implemented by 
pharmaceutical firms. Each therapeutic class’ regression was exposed to a vector of 
variables capturing the structure of the regulatory framework. Results: In general, 
prices do not show to be significant determinants of market shares, unlike factors 
associated with mechanisms of product differentiation do, proving they facilitate 
the development of brand loyalty and adherence, even with relatively higher prices. 
On the other hand, the inclusion of new active principles in the Compulsory Health 
Program (CHP) will act as a boost for priority prescriptions, while the production 
of generic medicines increases competition, reducing market shares. In addition, 
the impact of these policies rests heavily on the structure of competition in each 
therapeutic class. cOnclusiOns: The main health policy recommendations sug-
gest: the need to develop new areas of collaboration with the pharmaceutical sector, 
enhancing competition in markets with higher levels of concentration, facilitating 
the evaluation of policies on generic medicines, and successfully regularizing the 
structure of drugs and products available through the CHP.
PR3
POTENTIAl PUBlIC RESOURCE SAvINGS IN BRAzIl: THE SOMATROPIN CASE
Lemos LL1, Silva MR1, Santos JB2, Costa JD 1, Gomes RM1, Nascimento RC2, Almeida AM3, 
Guerra Júnior AA2
1CCATES, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2College of Pharmacy, Federal 
University of Minas Gerais, Belo Horizonte, Brazil, 3College of Medical Sciences of Minas Gerais, 
Belo Horizonte, Brazil
Objectives: Somatropin is provided in 4 and 12IU presentations by the Brazilian 
Unified Health System (SUS) for the treatment of Hypopituitarism (HP) and Turner 
Syndrome (TS). Other presentations are available in the market and are believed 
to provide a less costly treatment and/or less somatropin waste. MethOds: The 
registered medicines were obtained from the National Health Surveillance Agency 
(ANVISA) and their stability from package inserts. Monthly consumption and wast-
age analysis were estimated using the dose of somatropin for each disease and 
the average body weight of Minas Gerais State patients. Costs were estimated con-
sidering the Maximum Price of Sale to the Government from ANVISA. Results: 
Seventeen presentations (seven brands) of somatropin are available in the market 
and those with 28 days stability are not available in SUS. In general, medicines 
provided by SUS showed higher prices per IU. Immediate-use somatropin (4IU) 
showed the highest wastage and the highest cost estimates for both diseases. For 
HP, somatropin wastage of 4 and 12IU presentations was lower than that of the 
others available in the market. Regarding costs, they emerged in the fifth position 
of lower average cost for children and in the first and fifth positions for minimum 
and maximum doses for adults, respectively. For TS, monthly somatropin wast-
age was of 2.08-2.65IU for 4IU (7-14 days stability), slightly lower than that of 12 
to 18IU presentations. Medicines provided by SUS appeared in the ninth position 
of lower average cost. cOnclusiOns: Medicines incorporated by SUS presented 
the highest IU prices among registered medicines. Less wastage with incorporated 
presentations did not translate into better costs results (presentations of 15, 16 
and 18IU had lower or similar cost). The purchase of somatropin should be made 
allowing the participation of presentations of up to 18IU, with 7 to 28 days stability, 
and considering price per IU.
PR4
IMPACT OF MAjOR CHANGES TO THE BRAzIlIAN HEAlTH CARE SySTEM 
UTIlIzING THE HEAT MAPS PROjECT
Panish JM1, Junqueira Junior SM2, Cabra HA3, Hutzul T4, Hensen M5
1Ethicon, Somerville, NJ, USA, 2Johnson & Johnson Medical Brazil, São Paulo, Brazil, 3Johnson 
& Johnson Medical, México, D.F., Mexico, 4Johnson & Johnson Medical Products, Markham, ON, 
Canada, 5Pharmerit BV, Rotterdam, The Netherlands
Objective: To describe and understand the effects of various changes to the 
Brazilian Healthcare System, including a new guideline to elaborate HTA studies for 
Medical Devices, governmental price regulations, and demographics. MethOd: The 
Heat Maps project provides information from 17 major health care systems around 
the world, including Brazil. The Heat Maps capture: an overview of the healthcare 
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1.3% was observed (p< 0.001). For VAS-identified adherent patients, CVR decreased 
significantly by 4.4% from baseline to 90 days (p< 0.001). However, a significant 
decrease of 4.3% (p< 0.001) was also observed for VAS-identified non-adherent 
patients. cOnclusiOns: Patients identified as adherent using the first item of 
the BAAS showed significantly improved 10-year cardiovascular risk scores after 
90 days of treatment with valsartan, compared to patients who were identified as 
non-adherent. The VAS scale was not sufficiently sensitive to determine the effect 
of adherence on cardiovascular risk score.
Cv2
APIxABAN IN PATIENTS WITH ATRIAl FIBRIllATION: PATIENT 
CHARACTERISTICS OF THE lATIN AMERICA COHORT FROM A MUlTINATIONAl 
ClINICAl TRIAl
Avezum A1, Bahit MC2, Hermosillo JA3, Zanetti FL4, Perafan P5, Juarez-Garcia A6, Vulcano 
C7, Cubillos LA8, Korenblat Donato BM9
1Dante Pazzanese Institute of Cardiology, São Paulo, Brazil, 2INECO Neurociencias, Rosario, 
Argentina, 3Insto Nacional de Cardiología, México, DF, Mexico, 4Universidad de La Frontera, 
Temuco, Chile, 5Fundación Valle del Lili, Cali, Colombia, 6Bristol-Myers Squibb Company, México, 
DF, Mexico, 7Bristol-Myers Squibb, Buenos Aires, Argentina, 8Pfizer, New Jersey, NJ, USA, 9Bristol-
Myers Squibb, Wallingford, CT, USA
Objectives: Patients with Atrial fibrillation (AF), have a five-fold increase in 
the risk of stroke. Treatment for AF include stroke prevention therapy. Vitamin K 
antagonists (VKAs) have shown to prevent stroke in AF patients. Apixaban, a novel 
oral direct factor Xa inhibitor was studied in AF patients whom VKA therapy was 
unsuitable. Apixaban demonstrated clinical benefit in stroke or systemic embolism 
reduction without impacting the risk of major bleeding or intracranial hemorrhage. 
Patient characteristics of the Latin America (LA) cohort and overall population are 
presented. MethOds: Patients with AF at an increased risk for stroke and whom 
VKA therapy was unsuitable were randomized to receive apixaban (5 mg twice 
daily) or aspirin (81 to 324 mg) in a double blind trial. The study recruited from 36 
countries from September 2007 through December 2009. Five countries were from 
LA: Argentina, Brazil, Chile, Colombia, and Mexico. Patient characteristics from the 
LA cohort, is presented relative to the overall trial population. Results: Of5599 
patients in the trial, 1185 were from LA (21.2%). Mean age was similar, 71.5 and 70 
for LA and overall cohort respectively. 55% and 58% were males for LA and overall 
cohort respectively. The LA and overall cohorts had similar rates of prior stroke or 
TIA, diabetes mellitus and hypertension receiving treatment, at enrollment. Mean 
CHADS2 score at enrollment was 2,.0 for the apixaban arm and 2.1 for the ASA arm, 
which is the same for cohorts. Other baseline characteristics were similar. Region 
subgroup analysis revealed no statistically significant (p> 01.0) interactions between 
treatment effects and geographic region. cOnclusiOns: Baseline demographic and 
disease characteristics data from the LA cohort were similar to that of the clinical 
trial population. Results, in terms of safety and efficacy, given the total population 
trial, are expected to be consistent since interaction between treatment effects and 
geography was not significant.
Cv3
ARETAEUS: RETROSPECTIvE STUDy OF MEDICATION USAGE PATTERNS 
FOllOWING THE DIAGNOSIS OF TyPE 2 DIABETES IN lATIN AMERICA
Gagliardino JJ1, Granell RA2, Eliaschewitz FG3, Iglay K4, Brodovicz K4, Yu S4, González CD4, 
Shankar R4, Heisel O5, Bloomfield S5, Keown P5, Tunceli K6
1Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), Buenos Aires, 
Argentina, 2Instituto Mexicano del Seguro Social, Guadalajara, Mexico, 3CPClin Clinical Research 
Center, São Paulo, Brazil, 4Merck & Co., Inc., Kenilworth, NJ, USA, 5Syreon Corporation, Vancouver, 
BC, Canada, 6Merck & Co., Inc., North Wales, PA, USA
Objectives: To examine the initiation of oral antihyperglycemic agents (OAHAs) 
and/or statins in patients with type 2 diabetes mellitus (T2DM) and assess the time 
elapsed from diagnosis to treatment initiation and intensification when goals were 
not achieved in real world practice. MethOds: A retrospective study was performed 
on 662 medical records of patients with T2DM, diagnosed 24 to 48 months prior to 
signing the informed consent. The study included thirty-one general practitioner/
specialist sites across Mexico, Argentina and Brazil. Inclusion criteria: age ≥ 21 years 
at diagnosis; complete record of pre-diagnosis medication and pre-existing CV risk 
factors and 2 years follow-up records. Exclusion criteria: type 1 diabetes; pregnancy; 
receiving antihyperglycemic agents or statins prior to diagnosis; initially treated 
with insulin after T2DM diagnosis; or clinical trial participation during the study 
period. Descriptive statistics were used for demographic/clinical characteristics. 
Kaplan-Meier test was used to examine time to treatment and cumulative treat-
ment probability and multivariate logistic regression examined factors associated 
with such treatment. Results: At diagnosis, patients had a mean age of 53 years; 
44% had hypertension, 42% were obese and 23% had hypercholesterolemia. During 
the 2-year follow-up period, 93% were treated with OAHAs but only 29% of those 
eligible for statin therapy received statins. Time elapsed before first prescription of 
OAHA was 59±141 (Mean±SD) and 1 (1, 31) (median [IQR]) days and 230±232 days and 
132 (30, 406) days for statin. No variables were associated with OAHA initiation but 
family history of T2DM and hypercholesterolemia at diagnosis were associated with 
statin initiation. No antihyperglycemic treatment intensification was recorded in 
51%/53% of patients with HbA1c/FPG values above treatment targets during the fol-
low-up period. cOnclusiOns: The delay in treatment of hypercholesterolemia and 
intensification of treatment for hyperglycemia in patients with T2DM not attain-
ing treatment targets works against effective prevention of chronic complications.
Cv4
ECONOMICS OF DIABETES MEllITUS: THEORy AND EvIDENCE FOR BRAzIlIAN 
DATA IN 2008
Balbinotto G, Wiest R, Jacinto P
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
intROductiOn: Diabetes Mellitus (DM) is characterized by the high level of blood 
glucose. Ministry of Health data estimated that Brazil had about 10 million DM cases 
BI3
FINANCIAl IMPACT OF HOSPITAl ExPENDITURE IN CHRONIC DISEASES FOR 
SEGURO POPUlAR
Rodríguez-Aguilar R, Gutiérrez-Delgado C
Economic Analysis Unit, Mexico City, Mexico
Objectives: Estimate the expenditure in hospital services for cardio-vascular 
(CVD), malignant tumors (MT) and diabetes financed by Seguro Popular (SP) for 2004-
2012 in order to evaluate its midterm financial sustainability. MethOds: Hospital 
costs for interventions financed by SP for year 2012. Related hospital discharges 
from the SAEH for 2004-2012. Multiplication of both data generated the cost per 
ICD-10. The product was then grouped by GBD. Total hospital expenditure for SP, 
obtained from SINAIS for 2004-2012, was distributed using the cost per GBD. Then 
the proportion of hospital expenditure related to CVD, MT and diabetes is esti-
mated. Results: Mexico is one of the countries with the highest prevalence of child 
and adult overweight and obesity (O&O). That situation imposes a great pressure 
into SP to face an increasing demand of health care for non-communicable chronic 
diseases (NCD) particularly diabetes, MT and CVD. The average annual hospital 
expenditure of these groups of diseases represents about USD$273.4 million in 2012 
(9.7% of hospital expenditure). Malignant tumors that contributed the most were 
breast and cervical cancer with 90% of the total expenditure for this group. Acute 
myocardial infarction represents 66% of total expenditure for cardio-vascular. Under 
the status quo an increase of 65% in the cost of this group of diseases is expected 
for 2018. cOnclusiOns: Findings show an increased financial burden for SP gen-
erated by the selected NCD. The impact on the public budget that represents this 
level of hospital expenditure would threaten the sustainability of the SP if current 
trends hold. Given the demographic transition and level of O&O as risk factors for 
developing NCD in the coming years it is necessary to strengthen prevention and 
health promotion to reduce both new cases of NCD and complications in order to 
decrease their future impact on the SP budget.
BI4
HOSPITAlIzATION COSTS OF TyPE 2 DIABETES MEllITUS (T2DM) PATIENTS IN 
A PUBlIC HOSPITAl IN BRAzIl
Saad R1, Piedade A2, Wiens A1, Baptista DR1, Pontarolo R1
1Universidade Federal do Paraná, Curitiba, Brazil, 2Evidências - Kantar Health, Campinas, Brazil
Objectives: Diabetes is considered an outpatient care condition, manageable in 
the primary care setting, but which complications may lead to hospitalization. There 
is limited data on the costs of patients hospitalized due to diabetes in Brazil. We 
aimed to estimate the percentage of type-2 diabetes mellitus (T2DM) patients who 
were hospitalized and the mean cost per hospitalization within a public hospital in 
Brazil (SUS). MethOds: T2DM outpatients followed at the Hospital das Clínicas of 
Universidade Federal do Paraná (HC-UFPR) between 2011 and 2014 were eligible. Data 
from the last year of treatment were collected and validated within medical charts. 
We assessed demographics, hospitalization and cause, length and average costs 
per day of hospitalization. Exchange rate was 1.00USD = 3.21BRL. The study was 
approved by HC-UFPR IRB. Results: A total of 728 patients with T2DM were evalu-
ated, of which 38 (5.2%, 22 females and 17 males) were hospitalized due to eight dif-
ferent causes. Mean age was 64 years (44 to 84). Main reason for hospitalization was 
cardiovascular related problems (58.5%), followed by decompensated diabetes treat-
ment (17.0%) and kidney problems (9.4%). Average daily cost ranged from 907BRL 
(~283USD) (Neurology Center) to 2218BRL (~691USD) (Intensive Cardiology Therapy 
Center). The amount spent on the Cardiology Center represented 27.5% (188,244BRL) 
(~58,643USD) of the total, followed by Intensive Cardiology Therapy Center with 
18.1% (124,189BRL) (~38,688USD). Total hospital spending with 38 hospitalizations 
was 685,058BRL (~213,414USD) and mean length of hospitalization was 10 days 
(1 to 30 days). Mean cost per patient was 18,028BRL (~5,616USD). cOnclusiOns: 
Hospitalized patients with T2DM represent a significant burden to healthcare pay-
ers. However, the amount spent by the hospital is not necessarily the same reim-
bursed by the Brazilian Public Healthcare System (SUS), which hinders the estimate 
of the burden for the system as a whole.
CARDIOvASCUlAR DISEASE & DIABETES RESEARCH STUDIES
Cv1
ASSOCIATION OF ADHERENCE STATUS AS MEASURED USING TWO SINGlE-
ITEM PHySICIAN-ADMINISTERED METHODS WITH CARDIOvASCUlAR RISk IN 
PATIENTS TAkING ANTIHyPERTENSIvE MEDICATION
Rivera O1, Morales F2, Cordova P2, Fernández P2, López M2, MacDonald K3, Levengood M4, 
Vancayzeele S5, Aerts A5, Denhaerynck K3, Abraham I4, Villa L2
1Universidad de Concepción, Concepción, Chile, 2Facultad de Farmacia, Universidad de Concepción, 
Concepción, Chile, 3Matrix 45, Tucson, AZ, USA, 4The University of Arizona, Tucson, AZ, USA, 
5N.V. Novartis Pharma S.A., Vilvoorde, Belgium
Objectives: In patients with hypertension, non-adherence to prescribed treatment 
may contribute to a significant increase in cardiovascular risk. The aims of this 
study were (1) to examine if two single-item physician-administered adherence 
scales are predictive of cardiovascular risk and (2) to evaluate whether adherence 
to antihypertensive medications is associated with at least a one percent reduction 
in cardiovascular risk over 90 days. MethOds: Pooling data from seven observa-
tional studies, this analysis included 8,438 hypertensive patients taking valsartan. 
A ten-year cardiovascular risk (CVR) score was estimated following the risk scoring 
system proposed by the SCORE project in Europe. CVR score considered the following 
variables: age, total cholesterol, current smoking status, systolic blood pressure, and 
sex. At baseline and 90 days, physicians administered two single-item measures of 
adherence: the first item of the Basel Assessment of Adherence Scale (BAAS) and the 
Visual Analogue Scale (VAS). Results: At 90 days, males (4,257) had a significantly 
higher CVR than females (4,091) (p< 0.001). For BAAS-identified adherent patients, 
CVR decreased significantly by 2.6% from baseline to 90 days (p-value< 0.001). For 
BAAS-identified non-adherent patients, a significant but smaller decrease in CVR of 
